Elevated circulating ADGV was associated with a 1.52 to 1.79-fold increased odds of prevalent hypertriglyceridemia in adults aged 30-65 in Southern China after multivariable adjustment.
Observational (n=588)
Yes
Is elevated circulating ADGV associated with an increased risk of prevalent and incident hypertriglyceridemia?
Higher circulating ADGV is independently associated with prevalent and incident hypertriglyceridemia, suggesting it may serve as a biomarker and contributory factor in early dyslipidemia and hepatic lipogenesis.
Effect estimate: OR 1.52-1.79 across adjusted models
Absolute Event Rate: 51.02% vs 36.73%
p-value: p=<0.05
Higher circulating ADGV was independently associated with prevalent and incident hypertriglyceridemia across a cross-sectional cohort and an independent prospective cohort, and hepatocyte experiments support a contributory role of ADGV in hepatic lipogenesis.
Han et al. (Sat,) conducted a observational in Adults aged 30-65 years residing in Southern China with or without hypertriglyceridemia and metabolic abnormalities (n=588). Elevated circulating asymmetric dimethylguanidino valeric acid (ADGV) vs. Lower ADGV levels (below median) was evaluated on Prevalent hypertriglyceridemia (fasting triglyceride concentration ≥ 1.7 mmol/L) (OR 1.52-1.79 across adjusted models, p=<0.05). Elevated circulating ADGV was associated with a 1.52 to 1.79-fold increased odds of prevalent hypertriglyceridemia in adults aged 30-65 in Southern China after multivariable adjustment.